Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of lenabasum in diffuse cutaneous systemic sclerosis
MOH_2018-04-23_002250Phase 3Completed
- Sponsor
- Corbus Pharmaceuticals, Inc
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lenabasum in systemic sclerosis (SSc) (3 arms), sponsored by Corbus Pharmaceuticals, Inc. Primary endpoints: Efficacy in systemic sclerosis symptoms and complications, Quality of life improvement and 1 more. Started Mar 2018; status: completed.
02
Drugs
lenabasum
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on MOH_2018-04-23_002250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-04-23_002250.